Monte Rosa Therapeutics, Inc. Financials
This page shows Monte Rosa Therapeutics, Inc. (GLUE) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Monte Rosa Therapeutics, Inc. has an operating margin of -107.3%, meaning the company retains $-107 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses.
Monte Rosa Therapeutics, Inc. carries a low D/E ratio of 0.97, meaning only $0.97 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 75/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 2.40, Monte Rosa Therapeutics, Inc. holds $2.40 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 76/100.
Monte Rosa Therapeutics, Inc. converts 50.3% of revenue into free cash flow ($38.0M). This strong cash generation earns a score of 100/100.
Monte Rosa Therapeutics, Inc. passes 4 of 9 financial strength tests. 3 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
For every $1 of reported earnings, Monte Rosa Therapeutics, Inc. generates $-0.58 in operating cash flow ($42.0M OCF vs -$72.7M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.
Key Financial Metrics
Monte Rosa Therapeutics, Inc. generated $75.6M in revenue in fiscal year 2024.
Monte Rosa Therapeutics, Inc.'s EBITDA was -$73.0M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 45.9% from the prior year.
Monte Rosa Therapeutics, Inc. generated $38.0M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 160.5% from the prior year.
Monte Rosa Therapeutics, Inc. reported -$72.7M in net income in fiscal year 2024. This represents an increase of 46.3% from the prior year.
Monte Rosa Therapeutics, Inc. earned $-0.98 per diluted share (EPS) in fiscal year 2024. This represents an increase of 62.7% from the prior year.
Monte Rosa Therapeutics, Inc. held $224.3M in cash against $0 in long-term debt as of fiscal year 2024.
Monte Rosa Therapeutics, Inc. had 62M shares outstanding in fiscal year 2024. This represents an increase of 22.7% from the prior year.
Monte Rosa Therapeutics, Inc.'s operating margin was -107.3% in fiscal year 2024, reflecting core business profitability.
Monte Rosa Therapeutics, Inc.'s net profit margin was -96.1% in fiscal year 2024, showing the share of revenue converted to profit.
Monte Rosa Therapeutics, Inc. invested $121.6M in research and development in fiscal year 2024. This represents an increase of 9.2% from the prior year.
Monte Rosa Therapeutics, Inc. invested $4.0M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 79.1% from the prior year.
GLUE Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $12.8M-45.0% | $23.2M-72.7% | $84.9M+40.0% | $60.6M+558.1% | $9.2M+96.3% | $4.7M+341.3% | $1.1M | $0 |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $36.7M+19.7% | $30.7M-4.8% | $32.2M-17.2% | $38.9M+40.7% | $27.6M-1.6% | $28.1M+3.8% | $27.0M-0.4% | $27.1M |
| SG&A Expenses | $9.1M+12.0% | $8.1M-7.0% | $8.7M-0.8% | $8.8M+8.0% | $8.1M-12.4% | $9.3M+3.3% | $9.0M+16.3% | $7.7M |
| Operating Income | -$33.0M-112.0% | -$15.6M-135.3% | $44.0M+238.6% | $13.0M+149.0% | -$26.5M+18.7% | -$32.6M+6.6% | -$34.9M-0.2% | -$34.9M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | -$3.2M-365.0% | $1.2M+45.9% | $822K-62.0% | $2.2M+2947.9% | $71K-71.8% | $252K+203.6% | $83K+477.3% | -$22K |
| Net Income | -$27.1M-120.3% | -$12.3M-126.2% | $46.9M+248.9% | $13.4M+156.3% | -$23.9M+21.3% | -$30.3M+5.2% | -$32.0M+3.9% | -$33.3M |
| EPS (Diluted) | $-0.33-120.0% | $-0.15-126.3% | $0.57+111.1% | $0.27+193.1% | $-0.29+32.6% | $-0.43+18.9% | $-0.53+7.0% | $-0.57 |
GLUE Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $459.8M+27.9% | $359.6M-8.5% | $393.2M-10.4% | $438.7M+39.2% | $315.1M-8.4% | $344.1M+29.0% | $266.7M-12.2% | $303.8M |
| Current Assets | $401.8M+34.2% | $299.5M-9.9% | $332.3M-12.0% | $377.4M+50.3% | $251.2M-9.6% | $277.9M+39.6% | $199.0M-15.7% | $236.2M |
| Cash & Equivalents | $208.3M+200.1% | $69.4M-11.6% | $78.5M-65.0% | $224.3M+78.6% | $125.6M+15.4% | $108.8M+9.1% | $99.8M-22.1% | $128.1M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | $9.0M | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $214.0M+133.9% | $91.5M-22.5% | $118.0M-45.3% | $215.8M+96.9% | $109.6M-8.2% | $119.4M+4.6% | $114.2M-8.3% | $124.5M |
| Current Liabilities | $61.4M+46.8% | $41.9M-29.3% | $59.2M-62.3% | $156.9M+276.9% | $41.6M-1.7% | $42.3M+2.6% | $41.3M-11.4% | $46.6M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $245.8M-8.3% | $268.1M-2.6% | $275.2M+23.4% | $222.9M+8.5% | $205.5M-8.6% | $224.7M+47.3% | $152.5M-14.9% | $179.3M |
| Retained Earnings | -$431.1M-6.7% | -$404.0M-3.1% | -$391.7M+10.7% | -$438.6M+3.0% | -$452.0M-5.6% | -$428.2M-7.6% | -$397.9M-8.7% | -$365.9M |
GLUE Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $100.4M+389.3% | -$34.7M+23.7% | -$45.5M-135.3% | $128.9M+714.1% | -$21.0M+24.4% | -$27.8M+27.2% | -$38.2M-228.8% | $29.6M |
| Capital Expenditures | $651K-61.6% | $1.7M+6.8% | $1.6M+767.2% | $183K-54.1% | $399K-80.3% | $2.0M+46.1% | $1.4M-18.1% | $1.7M |
| Free Cash Flow | $99.8M+374.0% | -$36.4M+22.7% | -$47.1M-136.6% | $128.7M+701.8% | -$21.4M+28.2% | -$29.8M+24.7% | -$39.5M-241.5% | $27.9M |
| Investing Cash Flow | $38.1M+50.6% | $25.3M+125.3% | -$100.2M-224.4% | -$30.9M-181.8% | $37.7M+161.7% | -$61.2M-720.7% | $9.9M-31.1% | $14.3M |
| Financing Cash Flow | $348K-4.7% | $365K+2507.1% | $14K-97.7% | $608K+3953.3% | $15K-100.0% | $98.0M+39746.7% | $246K-99.0% | $25.2M |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
GLUE Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -258.3%-191.2pp | -67.1%-118.9pp | 51.8%+30.4pp | 21.4%+309.3pp | -287.8%+407.4pp | -695.3%+2589.2pp | -3284.5% | N/A |
| Net Margin | -212.1%-159.1pp | -53.0%-108.2pp | 55.2%+33.0pp | 22.2%+281.1pp | -258.9%+386.7pp | -645.6%+2358.9pp | -3004.5% | N/A |
| Return on Equity | N/A | N/A | 17.0%+11.0pp | 6.0% | N/A | N/A | N/A | N/A |
| Return on Assets | -5.9%-2.5pp | -3.4%-15.3pp | 11.9%+8.9pp | 3.1%+10.6pp | -7.6%+1.2pp | -8.8%+3.2pp | -12.0%-1.0pp | -10.9% |
| Current Ratio | 6.54-0.6 | 7.16+1.5 | 5.61+3.2 | 2.40-3.6 | 6.03-0.5 | 6.56+1.7 | 4.82-0.2 | 5.07 |
| Debt-to-Equity | 0.87+0.5 | 0.34-0.1 | 0.43-0.5 | 0.97+0.4 | 0.530.0 | 0.53-0.2 | 0.75+0.1 | 0.69 |
| FCF Margin | 781.5%+938.5pp | -157.0%-101.6pp | -55.4%-267.7pp | 212.3%+444.4pp | -232.1%+402.4pp | -634.5%+3082.5pp | -3717.0% | N/A |
Similar Companies
Frequently Asked Questions
What is Monte Rosa Therapeutics, Inc.'s annual revenue?
Monte Rosa Therapeutics, Inc. (GLUE) reported $75.6M in total revenue for fiscal year 2024. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Monte Rosa Therapeutics, Inc. profitable?
No, Monte Rosa Therapeutics, Inc. (GLUE) reported a net income of -$72.7M in fiscal year 2024, with a net profit margin of -96.1%.
What is Monte Rosa Therapeutics, Inc.'s earnings per share (EPS)?
Monte Rosa Therapeutics, Inc. (GLUE) reported diluted earnings per share of $-0.98 for fiscal year 2024. This represents a 62.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Monte Rosa Therapeutics, Inc.'s EBITDA?
Monte Rosa Therapeutics, Inc. (GLUE) had EBITDA of -$73.0M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Monte Rosa Therapeutics, Inc.'s operating margin?
Monte Rosa Therapeutics, Inc. (GLUE) had an operating margin of -107.3% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Monte Rosa Therapeutics, Inc.'s net profit margin?
Monte Rosa Therapeutics, Inc. (GLUE) had a net profit margin of -96.1% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Monte Rosa Therapeutics, Inc.'s free cash flow?
Monte Rosa Therapeutics, Inc. (GLUE) generated $38.0M in free cash flow during fiscal year 2024. This represents a 160.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Monte Rosa Therapeutics, Inc.'s operating cash flow?
Monte Rosa Therapeutics, Inc. (GLUE) generated $42.0M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Monte Rosa Therapeutics, Inc.'s total assets?
Monte Rosa Therapeutics, Inc. (GLUE) had $438.7M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Monte Rosa Therapeutics, Inc.'s capital expenditures?
Monte Rosa Therapeutics, Inc. (GLUE) invested $4.0M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Monte Rosa Therapeutics, Inc. spend on research and development?
Monte Rosa Therapeutics, Inc. (GLUE) invested $121.6M in research and development during fiscal year 2024.
How many shares does Monte Rosa Therapeutics, Inc. have outstanding?
Monte Rosa Therapeutics, Inc. (GLUE) had 62M shares outstanding as of fiscal year 2024.
What is Monte Rosa Therapeutics, Inc.'s current ratio?
Monte Rosa Therapeutics, Inc. (GLUE) had a current ratio of 2.40 as of fiscal year 2024, which is generally considered healthy.
What is Monte Rosa Therapeutics, Inc.'s debt-to-equity ratio?
Monte Rosa Therapeutics, Inc. (GLUE) had a debt-to-equity ratio of 0.97 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Monte Rosa Therapeutics, Inc.'s return on assets (ROA)?
Monte Rosa Therapeutics, Inc. (GLUE) had a return on assets of -16.6% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Monte Rosa Therapeutics, Inc.'s Piotroski F-Score?
Monte Rosa Therapeutics, Inc. (GLUE) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Monte Rosa Therapeutics, Inc.'s earnings high quality?
Monte Rosa Therapeutics, Inc. (GLUE) has an earnings quality ratio of -0.58x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Monte Rosa Therapeutics, Inc.?
Monte Rosa Therapeutics, Inc. (GLUE) scores 63 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.